| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 281,080 | 306,744 | ||
| Short-term investments | 1,430,240 | 1,354,683 | ||
| Prepaid expenses and other current assets | 55,847 | 54,348 | ||
| Total current assets | 1,767,167 | 1,715,775 | ||
| Property and equipment, net | 253,486 | 242,266 | ||
| Operating lease right-of-use assets | 83,515 | 85,649 | ||
| Long-term investments | 959,256 | 1,165,091 | ||
| Restricted cash | 1,468 | 1,319 | ||
| Other assets | 106,708 | 95,263 | ||
| Total noncurrent assets | 1,404,433 | 1,589,588 | ||
| Total assets | 3,171,600 | 3,305,363 | ||
| Accounts payable | 48,962 | 31,414 | ||
| Accrued compensation | 16,762 | 10,830 | ||
| Accrued contract manufacturing expenses | 103,959 | 73,726 | ||
| Accrued expenses | 24,592 | 32,214 | ||
| Operating lease liabilities current | 5,771 | 6,302 | ||
| Total current liabilities | 200,046 | 154,486 | ||
| Operating lease liabilities long-term | 78,672 | 79,543 | ||
| Total liabilities | 278,718 | 234,029 | ||
| Common stock, 0.001 par value 500,000,000 shares authorized at september30, 2025 and december31, 2024 130,029,111 and 124,893,034 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 133 | 133 | ||
| Additional paid-in capital | 4,800,333 | 4,768,698 | ||
| Accumulated other comprehensive loss | 856 | -1,887 | ||
| Accumulated deficit | -1,908,440 | -1,695,610 | ||
| Total stockholders' equity | 2,892,882 | 3,071,334 | ||
| Total liabilities and stockholders' equity | 3,171,600 | 3,305,363 | ||
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)